retatrutide triple hormone receptor agonist obesity In a 48-week trial, Retatrutide, a Triple-Hormone-Receptor Agonist, contributed to a maximum body weight decrease of 24.2%, significantly outperforming the placebo. Original Article: Triple–Hormone-Receptor for — A Phase 2 Retatrutide is a triple-agonist drug
Pay in 4 interest-free payments of $6.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6





30024-X/asset/e1f51155-083e-4b9c-a610-b644a7d7168b/main.assets/gr1.gif)





















